Safety and effectiveness of balloon cryoablation for treatment of Barrett’s associated neoplasia: systematic review and meta-analysis

Abstract

Background and study aims Balloon cryoablation (BC) is a novel procedure for endoscopic ablation of Barrett’s esophagus (BE- associated neoplasia. We performed a meta-analysis to assess the feasibility, effectiveness, and safety of BC for treatment of BE neoplasia.

Patients and methods Several databases were searched for relevant articles (PubMed, Web of Science, Google Scholar, EMBASE) as well as abstracts of recent gastroenterology meetings. Data extraction was performed by two investigators using standardized forms, including age, gender, length of BE segment, prior treatments, procedural time and number ablation sessions, technical feasibility, adverse events, and eradication rates of intestinal metaplasia (CE-IM) and dysplasia (CE-D) at follow-up. Quality of the studies was assessed using a modified Newcastle Ottawa Scale.

Results Seven studies met inclusion criteria for a total of 548 ablation sessions in 272 patients. The most common histopathology reported prior to BC was high-grade dysplasia (n = 131), followed by low-grade dysplasia (n = 75), and intramucosal adenocarcinoma (n = 52). The pooled rate for technical feasibility was 95.8 % (95 % CI: 93.6–97.5 %; I² = 13.2 %; P = 0.3). Pooled rates of CE-IM and CE-D were 85.8 % (95 % CI: 77.8–92.2 %, I² = 55.5 %; p = 0.04) and 93.8 % (95 % CI: 85.5–98.7 %, I² = 74.2 %; P = 0.001), respectively. The overall adverse event (AE) rate was 12.5 % (34 out of 272 patients), of which stricture formation was the most common (5.8 %), followed by mucosal laceration (0.7 %), perforation (0.4 %), and bleeding (0.4 %). All AEs were successfully managed endoscopically.

Conclusion This meta-analysis suggests that BC is a safe and effective ablative technique for treatment of BE neoplasia; future prospective comparative trials are needed to corroborate these initial findings.

• References

• 1 de Jonge PJ, van Blankenstein M, Looman CW. et al. Risk of malignant progression in patients with Barrettʼs oesophagus: a Dutch nationwide cohort study. Gut 2010; 59: 1030-1036
• 2 Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1245-1255
• 3 Phoa KN, Van Vilsteren FG, Weusten BL. et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014; 31: 1209-1217
• 4 Yang D, Othman M, Draganov PV. Endoscopic Mucosal Resection vs. Endoscopic submucosal dissection for Barrett’s esophagus and colorectal neoplasia. Clin Gastroenterol Hepatol 2018; 3: 1021-1028
• 5 Yang D, Zou F, Xiong S. et al. Endoscopic submucosal dissection for early Barrett’s neoplasia: a meta-analysis. Gastrointest Endosc 2018; 87: 1383-1393
• 6 Johnston CM, Schoenfeld LP, Ysore JV. et al. Endoscopic spray cryotherapy: a new technique for mucosal ablation in the esophagus. Gastrointest Endosc 1999; 50: 86-92
• 7 Visrodia K, Zakko L, Singh S. et al. Cryotherapy for persistent Barrett’s esophagus after radiofrequency ablation: a systematic review and meta-analysis. Gastrointest Endosc 2018; 87: 1396-1404
• 8 Friedland S, Triadafilopoulos G. A novel device for ablation of abnormal esophageal mucosa (with video). Gastrointest Endosc 2011; 74: 182-188
• 9 Canto MI, Shaheen NJ, Almario JA. et al. Multifocal nitrous oxide cryoballoon ablation with or without EMR for treatment of neoplastic Barrett’s esophagus (with video). Gastrointest Endosc 2018; 88: 438-446
• 10 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605
• 11 Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol 2001; 1: 7
• 12 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 18: 264-269
• 13 Stroup DF, Berlin JA, Morton SC. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting; meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 15: 2008-2012
• 14 Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011; 10: 342-349
• 15 Trindade AJ, Canto MI. Circumferential treatment of long-segment Barrett’s esophagus using the next-generation cryoballoon. Endoscopy 2019; 4: E69-E70
• 16 Castela J, Demedts I, Bisschops R. Treatment of low grade dysplasia in Barrett’s esophagus with a new-generation cryoballoon device. Endoscopy 2018; 11: E318-E319
• 17 Louie BE, Hofstetter W, Triadafilopoulos G. et al. Evaluation of a novel cryoballoon swipe ablation system in bench, porcine, and human esophagus models. Dis Esophagus 2018; 8: 1-7
• 18 Canto MI, Abrams JA, Kunzli HT. et al. Nitrous oxide cryotherapy for treatment of esophageal squamous cell neoplasia: initial multicenter international experience with a novel cryoballoon ablation system (with video). Gastrointest Endosc 2018; 2: 574-581
• 19 Schölvinck DW, Künzli HT, Kestens C. et al. Treatment of Barrett’s esophagus with a novel focal cryoablation device: a safety and feasibility study. Endoscopy 2015; 47: 1106-1112
• 20 Wang KK, Chen AM, Friedland S. et al. Tu1592 Multi-Center Experience With the Cryoballoon Focal Ablation System (CAS) for Esophageal Dysplasia. Gastrointest Endosc 2015; 81: AB522
• 21 Sitaraman L, Lightdale CJ, Abrams JA. Use of the Cryoballoon focal ablation system for the eradication of esophageal neoplasia: a single-center experience. Gastroenterology 2016; 150: S266
• 22 Künzli HT, Schölvinck DW, Meijer SL. et al. Efficacy of the CryoBalloon Focal Ablation System for the eradication of dysplastic Barrett’s esophagus islands. Endoscopy 2017; 49: 169-175
• 23 van Munster SN, Overwater A, Haidry R. et al. Focal cryoballoon versus radiofrequency ablation of dysplastic Barrett’s esophagus: impact on treatment response and postprocedural pain. Gastrointest Endosc 2018; 88: 795-803
• 24 Canto MI, Trindade AJ, Abrams J. et al. Safety and efficacy of multifocal cryoballoon ablation for eradiction of previously untreated Barrett’s neoplasia: preliminary results of a large multicenter American trial. Gastrointest Endsoc 2019; 89: AB98
• 25 Suchniak-Mussari K, Dye CE, Moyer MT. et al. Efficacy and safety of liquid nitrogen cryotherapy for treatment of Barrett’s esophagus. World J Gastrointest Endosc 2017; 16: 480-485
• 26 Trindade AJ, Pleskow DK, Sengupta N. et al. Efficacy of liquid nitrogen cryotherapy for Barrett's esophagus after endoscopic resection of intramucosal cancer: a multicenter study. J Gastroenterol Hepatol 2018; 33: 461-465
• 27 Shaheen NJ, Greenwald BD, Peery AF. et al. Safety and efficacy of endoscopic spray cryotherapy for Barrettʼs esophagus with high-grade dysplasia. Gastrointest Endosc 2010; 71: 680-685
• 28 Ghorbani S, Tsai FC, Greenwald BD. et al. Safety and efficacy of endoscopic spray cryotherapy for Barrettʼs dysplasia: results of the National Cryospray Registry. Dis Esophagus 2016; 29: 241-247
• 29 Dumot JA, Vargo JJ, Falk GW. et al. An open-label, prospective trial of cryospray ablation for Barrett’s esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc 2009; 70: 635-644
• 30 Cholapranee A, Trindade AJ. Challenges in endoscopic therapy of dysplastic Barrett’s esophagus. Curr Treat Options Gastroenterol 2019; 17: 32-47
• 31 Trindade AJ, Canto MI. Circumferential treatment of long-segment Barrett’s esophagus using the next-generation cryoballoon. Endoscopy 2019; 51: E69-E70